第二届西湖临床质谱研讨会
第二届西湖临床质谱研讨会
Progresses and Perspectives of Mass Spectrometry-based Clinical Proteomics
基于质谱的临床蛋白质组学的研究进展与展望
Co-chairs: Stephen Pennington, Fuchu He and Tiannan Guo
Supported by Westlake University, CNHUPO, HUPO
When: 04 Dec, 2020, 09:00-23:00 (UTC+8)
Where: Playbacks
Summary
The rapidly developing mass spectrometry-based proteomics is indispensable for precision medicine. However, its penetration into clinic has yet to prevail. One technical bottleneck is high throughput proteomic analysis of clinical specimens from (multi-center) cohort studies, whereas integrative analysis of proteomics data with clinical and other omics data poses another technical challenge. Moreover, the comprehension of the unmet clinical needs by the mass spectrometrists, and the understanding of the progresses and limitations of cutting-edge proteomic techniques by the clinicians are non-trivial. This symposium gathers experts from clinical medicine, proteomics and beyond, with a goal of building a complete picture of the MS-based clinical proteomics: the current status and the perspective for future development.
28
Speakers
10
Coordinators
2671
Online Participants
14.5
Hours
Yigong Shi 施一公
Westlake Universisty, 西湖大学
Ph.D.Principal Investigator, School of Life Sciences, Structural biology of cancer, with a focus on key regulatory components in the apoptotic pathways and other important cellular processe. Structural biology of important membrane proteins.Structural mechanisms of macromolecular machineries.
Ruedi Aebersold
ETH Zurich, Switzerland
Ruedi Aebersold is a Swiss and Canadian scientist trained at the Biocenter, University of Basel. He completed his Postdoctoral training at Caltech. He is a Professor at ETH Zurich and the University of Zurich. He was on the faculties of the Universities of British Columbia and Washington and co-founded, with Lee Hood and Alan Aderem, the Institute for Systems Biology in Seattle. He is on the SAB of a number of research organizations and has served as senior editor for Molecular and Cellular Proteomics and Molecular Systems Biology. He was elected as EMBO member in 2006.The research focus of his group is the proteome. The group has pioneered several widely used techniques and generated a range of open access/open source software and statistical tools that have contributed to making proteomic research results more transparent and accurate. The work has been recognized with numerous awards and prizes. More than 40 trainees of the group have reached faculty status at leading research institutions worldwide.
Fuchu He 贺福初
National Center for Protein Sciences, Beijing, 国家蛋白质科学中心（北京）
Dr. He is the leading scientist studying proteomics in China. He was the founder of CNHUPO and among the first group of people who founded HUPO in 2001. He was the first Chinese scientist who led an international consortium-Human Liver Proteome Project (HLPP), and the founder of Beijing Proteome Research Center, Phoenix Center (proteomics) and Institutes of Biomedical Sciences Fudan University. As the chief scientist, he has been propelling HLPP to the China Human Proteome Project (CNHPP), to create an encyclopedia of proteins in the human body under physiological and pathological conditions. Recently, his team stratified early hepatocarcinoma (HCC) into 3 proteomic subtypes with different clinical outcome. Some drug targetable proteins have been demonstrated useful in identifying patients with HCC who could potentially benefit from targeted treatment in further clinical trials. These studies demonstrated the proteomic analysis as an independent powerful tool in cancer molecular subtyping, indicating that the era of “Proteome Driven Precision Medicine (PDPM)” is coming.
Matthias Mann
Max Planck Institute, Germany
Matthias Mann studied physics and mathematics at Göttingen University and obtained his Ph.D. in chemical engineering at Yale, contributing to the Nobel Prize for his supervisor John Fenn for electrospray ionization. Since 2005 he is director at the Max Planck Institute of Biochemistry, Munich and since 2009 also director of the Department of Proteomics, Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen. He has obtained numerous prizes and is one of the most cited scientists with an h-factor of 232 and 250,000 total citations (Google Scholar). His work in sample preparation, chromatography, mass spectrometry and computer algorithms has been decisive in making mass spectrometry applicable to molecular biology. Apart from proteomics technology development his team works on fundamental cell and systems biological questions. Today they focus on clinically relevant topics, especially the analysis of the blood plasma proteome and cancer tissues at the single cell level.
Jun Qin 秦钧
National Center for Protein Sciences, Beijing, 国家蛋白质科学中心（北京）
Jun Qin is among the few people in the world, who can integrate MS instrument design, proteomic method development, bioinformatics, biology and clinical applications into one research program.
Bernhard Küster
Technische Universität Muenchen, Germany
Chair of Proteomics and Bioanalytics Technical University of Munich.Bernhard Kuster is a chemist by training and obtained is PhD in Biochemistry from the University of Oxford. He went on to do a PostDoc funded by an EMBO long-term fellowship at the EMBL in Heidelberg and the University of Southern Denmark in Odense. After seven years as VP Analytical Sciences and Informatics at the biotech firm Cellzome (now GSK), he became full professor of Proteomics at the Technical University of Munich in 2007. Bernhard currently serves as Vice Dean Information Management of the TUM School of Life Sciences, is the Director of the Bavarian Biomolecular Mass Spectrometry Center and a Carl von Linde Senior Fellow of the TUM Institute for Advanced Study. Bernhard’s research focuses on mass spectrometry based proteomics and its application to chemical and systems biology. He is particularly interested in i) which genes of an organism exist as proteins, where they are expressed and in which quantities, ii) how drugs interact with proteins, signaling pathways and cellular systems in order to understand their often multiple modes of action and iii) developing methods and tools to study proteomes. Bernhard has published over 200 papers on proteomics and bioinformatics that have been cited >30,000 times.
Catherine Wong 黄超兰
Peking University, 北京大学
Director, Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center. Principal Investigator, Center for Life Sciences, Peking Unversity & Tsinghua University Associate Professor with Tenure, School of Basic Medical Sciences, Peking University Health Science Center Principal Investigator, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center Honorary Professorship, Faculty of Biology, Medicine and Health, The University of Manchester The Introduction of Outstanding Talents for Technology, Chinese Academy of Sciences Committee Member of Center for Transformation of Scientific and Technological Achievements, Peking University Health Science Center Committee Member of Protein Society, The Chinese Society of Biochemistry and Molecular Biology Chairman Member of Committee of Experimental Medicine (Mass Spectrometry), National Association of Health Industry and Enterprise Management Committee Member of China Human Proteome Organisation
Markus Ralser
Charite University Medicine, Germany
Markus Ralser (*1980), Prof. Dr Mag, Einstein Professor of Biochemistry, is Head of the Dept. of Biochemistry at the Charitè University Medicine (the joint medical faculty of Humboldt and Free state Universities in Berlin, Germany) while being a Senior Group Leader at the Francis Crick Institute (London).Previously, he was a Group leader at the Department of Biochemistry, University of Cambridge, a positionhe took after being trained in mass spectrometry at VU Amsterdam (Netherlands), and being a Junior group at the Max Planck Institute for Molecular Genetics (Berlin). The Ralser lab is known for fundamental discoveries that have improved our understanding of how cells can coordinate hundreds of biochemical reactions assembled in the metabolic network, and for the development of high-throughput mass spectrometry technologies. Major publications from the Ralser lab have linked each yeast gene to its role in metabolism, have shown that metabolism is much more flexible and integrated into the physiology of cells as it was expected only a few years ago. Moreover, results obtained in the Ralser lab have provided fundamental insights on how central carbon metabolism could have evolved in early life forms, how reactions can co-occur within a cell despite competing chemistries, and how yeast and cancer cells reconfigure metabolism to be protected against oxidative stress. The Ralser lab is/has been the recipient of substantial funding by The Crick, the Wellcome Trust, the ERC, EMBO, the BMBF (Germany), the Max Planck Society and the BBSRC. He was selected into the EMBO Young investigator programme, he is a Wellcome Trust Beit fellow, and he is a recipient of the 2008 BioMed central Research Award, the 2017 Colworth Medal of the Biochemical Society, the 2019 Starling Medal of the Endocrinological Society. and the 2020 EMBO Gold medal.
Lanjuan Li 李兰娟
Zhejiang University, 浙江大学
Professor Lanjuan Li is a member of Chinese Academy of Engineering, and Professor/Chief Physician of Infectious Diseases, the 1st Affiliated Hospital, Zhejiang University. She also serves as the director of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Diagnosis and Treatment, the director of Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases. She has been engaged in clinical, teaching and research work of infectious diseases for about 40 years and served as editor-in-chief for 33 books, publishing more than 400 high-level international peer-reviewed articles (including Nature, Lancet and New England Journal of Medicine).
Shu Zheng 郑树
Zhejiang University, 浙江大学
The professor of Medicine department of Zhejiang University, and doctoral supervisor·The deputy director of the Development Committee of Zhejiang University·Director of the Cancer Institute Academic Committee of Zhejiang University=·Vice president of Chinese Anti-Cancer Association·Chairman of the Professional Committee of the National Colorectal Cancer·Executive director of the Chinese Medical Association
Yu-Ju, Chen
Academia Sinica
B.S., 1992, National Taiwan University. Ph.D., 1997, Iowa State University. Postdoctoral Research Fellow, 1997, Ames Laboratory; 1998-1999, National Tsing-Hua University. Assistant Research Fellow, 1999-2005; Associate Research Fellow, 2005-2010; Research Fellow, 2010-2019; Distinguished Research Fellow, 2019-present; Director, 2013-2019, Institute of Chemistry; Acting Director, 2019-present, Institute of Chemistry; Adjunct Research Fellow, 2004-present, Genomic Research Center, Academia Sinica. President, 2009-2011, Taiwan Proteomics Society. Editorial Board Member, 2008-present, European Journal of Mass Spectrometry. Council Member, 2009-present, AOHUPO.
Ruiping Xiao 肖瑞平
Peking University, NEJM
Dr. Xiao has made important discoveries in beta-adrenergic receptor (AR) subtype signaling, with an emphasis on translating bench discoveries to the bedside. She was the first to show that beta2-AR dually couples to Gs and Gi, revealing a new signaling paradigm of the G protein-coupled receptor superfamily. While chronic beta1-AR stimulation causes heart cell death and cardiomyopathy by Ca2+/calmodulin kinase II-dependent pathways, beta2-AR is cardiac protective. She co-invented the Gs-biased, chiral beta2-AR agonist R,R-feneterol and co-supervised its Phase I clinical trial (Phase II planned), spearheading a novel therapy treating heart failure with beta2-AR agonist R,R-feneterol or derivatives combined with beta1-AR blocker. Her current research has revealed that MG53 E3 ligase-mediated, ubiquitin-dependent degradation of insulin receptor and insulin receptor substrate 1 constitutes a fundamental mechanism for the development of systemic insulin resistance, leading to the sequelae of metabolic syndrome and cardiovascular complications. She has authored >140 peer-reviewed publications. She has been global leader in biomedical research and served as the founding director of the Institute of Molecular Medicine, Peking University since 2005. She has also played a leadership role in clinical translational research and currently serves as an Associate Editor of The New England Journal of Medicine。
Stephen Pennington
University College Dublin
Steve is currently Professor of Proteomics at the UCD School of Medicine & Conway Institute in Dublin, Ireland. He graduated from Imperial College of Science and Technology (Imperial College London) with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge. Steve and his research team are actively engaged in a number of collaborative proteomics projects focussed on comprehensive proteomics scale analysis of protein expression and function to support improved understanding of mechanisms of disease progression and diagnosis. They are currently focussed on the development of multiplexed protein biomarker measurements using multiple reaction monitoring mass spectrometry to support the translation of novel multiplexed blood protein biomarkers to clinical diagnostic tests.
Ruijun Tian 田瑞军
Southern University of Science and Technology, 南方科技大学
Dr. Ruijun Tian obtained his Ph.D. in analytical chemistry from Dalian Institute of Chemical Physics, Chinese Academy of Sciences in 2008 (Mentor: Dr. Hanfa Zou). He then moved to Canada for his postdoctoral training with Dr. Daniel Figeys at Ottawa Institute of Systems Biology, University of Ottawa (2008-2010) and Dr. Tony Pawson at Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and University of Toronto (2010-2014). He joined Department of Chemistry, Southern University of Science and Technology (SUSTech) in 2014 as an associate professor and was promoted as tenured full professor in 2020. He is also adjunct professor of School of Medicine, University of Ottawa and Shenzhen People’s hospital. His major research interest is precision medicine-oriented MS-based proteomics technology development and applications mainly in intercellular signaling of tumor microenvironment. He has published more than 70 research papers in Nature, PNAS, Angew Chem., Mol. Cell. Proteomics, Anal. Chem., etc. with H-index of 27 (Google Scholar). He received 2012 Young Investigator Award from International Association for Protein Structure Analysis and Proteomics (IAPSAP), Canadian Institutes of Health Research (CIHR) postdoctoral fellowship, and President’s Scholarship from Chinese Academy of Sciences. He was the co-chairs for 2nd Young Investigator Symposium of CNHUPO and 5th China-Canada Systems Biology Symposium. He is the editorial board member for Chinese Journal of Chromatography (Young pannel) and Frontiers in Endocrinology.
Chris W. Turck
Max Planck Institute of Psychiatry, Munich, Germany
Prof. Chris Turck is Head of Proteomics and Biomarkers at the Max Planck Institute of Psychiatry. He also holds faculty appointments in the Department of Biochemistry at the University of Munich, International Max Planck Research School of Molecular and Cellular Life Sciences. International Max Planck Research School of Translational Psychiatry and Graduate School of Systemic Neurosciences. After receiving his Ph.D. degree in Chemistry he carried out postdoctoral work at the Roche Institute of Molecular Biology. Subsequently he was recruited to the Faculty of Medicine at the University of California, San Francisco where he was Director of the Howard Hughes Medical Institute Protein Structure Laboratory and Associate Investigator at the Cardiovascular Research Institute. Prof. Turck serves on the ‘Neuroscience Steering Committee’ of the fNIH Biomarkers Consortium and is chair of the ABRF Metabolomics Research Group. He recently received President’s International Fellowship Initiative funding from the Chinese Academy of Sciences for a collaboration with the Kunming Institute of Zoology. His research efforts center on the identification of biosignatures for psychiatric disorders and the antidepressant drug response using -omics technologies to delineate affected molecular pathways. The goal is to complement imprecise clinical parameters with molecular biosignatures to improve patient diagnosis, stratification and treatment. https://www.psych.mpg.de/1495985/turck
Huiru Tang 唐惠儒
Fudan University, 复旦大学
Huiru Tang Professor, Biochemistry and Molecular Biology, Fudan University. Winner of National Outstanding Youth Science Foundation. He received a bachelor's degree from Northwestern Light Industry College (now Shaanxi University of Science and Technology) in 1986 and a doctorate from London University in 1994. From 1992 to 2000, he successively served as Research Scientist, Senior Research Scientist at BBSRC Food Research Institute. From 2001 to 2005, he served as Senior Scientist in Biochemistry Department of Biomedical Engineering, Imperial College London. From 2005 to 2014, he successively served as researcher and doctoral supervisor of Wuhan Institute of Physics and Mathematics, deputy director of research department and director of Key Laboratory of Biological Magnetic Resonance Analysis of Chinese Academy of Sciences. November 2014 Fudan University Distinguished Professor.
Roman Fischer
University of Oxford
Roman Fischer is an Associate Professor and Senior Group Leader in Clinical Proteomics at the University of Oxford. He leads the Discovery Proteomics Facility at the Target Discovery Institute. RF studied Biotechnology at the Technical University Braunschweig and obtained his PhD at the Helmholtz Centre for Infection Research for the analysis of host-pathogen interactions of Listeria monocytogenes using proteomic methods (2007). After postdoctoral studies on Il-1 signalling in the laboratory of Professor Sir Philip Cohen in Dundee (Scotland), RF started to develop clinical proteomics at the University of Oxford in 2009. Since 2013 RF leads the Discovery Proteomics Facility and applies proteomic methods to a multitude of scientific questions. Currently, RF focusses his research on the development of high-throughput and spatial proteomics methods and their application to large clinical cohorts and specimen.
Roger Reddel
The University of Sydney
Professor Roger Reddel is a medical oncologist, molecular geneticist and an internationally renowned expert on cancer cell immortalisation. He is Director of Children’s Medical Research Institute (CMRI), Westmead, a Fellow of the Australian Academy of Science, and a Fellow of the Australian Academy of Health and Medical Sciences. His research career on the cellular and molecular biology of immortalisation commenced as a postdoctoral scientist (Fulbright Fellow) at the National Cancer Institute, Maryland, USA, where he improved techniques for immortalisation of human cells in vitro and made the key finding that immortalisation is necessary for malignant transformation of human cells. He returned to Australia to establish and head the Cancer Research Unit at CMRI, with a fellowship from Cancer Council NSW, which has provided major support ever since. He is internationally recognised for research on the enzyme telomerase and for discovering ALT (Alternative Lengthening of Telomeres), which together contribute to unlimited growth in >95% of cancers. His team has made additional seminal findings regarding ALT and the manner in which it is repressed in normal (non-cancer) cells, and identified a molecular marker for ALT. Overall his research aims to help develop anti-cancer treatments that would work by blocking immortalisation, and tests for detecting signs of cellular immortalisation for early detection of cancer. Professor Reddel has won numerous awards including the Ramaciotti Medal for Excellence in Biomedical Research (2007), the 2011 NSW Premier's Award for Outstanding Cancer Researcher of the Year, and the Neil Hamilton Fairley Medal of the Royal Australasian College of Physicians (2017). He was a founding member of the University of Sydney's Cancer Research Network and chaired its Translational Research Committee. He is a member of the Board of Paediatrio, which has been set up to coordinate paediatric research in NSW.
Ping Xu 徐平
National Center for Protein Sciences, Beijing, 国家蛋白质科学中心（北京）
Dr. Xu is interested in studying novel biological functions of ubiquitin chains and regulation of protein ubiquitination in the occurrence and development of liver disease by proteomics approaches. His research involves state-of-art technologies for profiling thousands of proteins and posttranslational modifications by quantitative mass spectrometry and large scale data processing.
Anthony Whetton
University of Manchester
New systems biology approaches will transform biomedical research. One key strand of this new approach is proteomics/mass spectrometry. He has worked effectively with clinical colleagues in the field of haematology for many years. However, his interactions now encompass research into many other malignancies and, for example, diseases of pregnancy and the lungs, due to the development of an “outstanding” (metrics: LLR international panel who site visited in 2013) mass spectrometry/proteomics facility. He advises internationally leading clinician scientists/bioscientists on the use of mass spectrometry and proteomics in their research. This is essential; too often these complex systems biology approaches lead to failure because of poor experimental design and/or lack of awareness of the technique’s limitations. The development of new biomarkers and surrogate endpoint markers is a key requirement for clinical trials and closing the translational gap in medicine. The establishment of a platform for biomarker discovery and validation from biological fluids (more generally available than biopsy material) has been a growing theme of my research.
Jimin Shao 邵吉民
Zhejiang University, 浙江大学
Professor and Chair, Department of Pathology and Pathophysiology.Executive Director, Center for Cancer Research,Associate Dean, School of Basic Medical Sciences, Zhejiang University. Research: (1)Cancer-promoting inflammation and cancer stem cell plasticity. (2)Neoantigens identification and technology development for cancer immunotherapy. (3)Protein structure and function of anti-cancer therapeutic targets and novel drug discovery.
Hong Shen 沈宏
Roche Innovation Center Shanghai, 上海罗氏创新中心
Dr. Hong Shen received his B.S. from Peking University and Ph.D. from Stanford University. After 9 years working at Merck in the US, he joined Roche Innovation Center Shanghai (RICS) in 2012. Dr. Shen is now the Site Head of RICS. Dr. Shen’s experience in drug discovery includes the areas of hypertension, diabetes, thrombosis, atherosclerosis, obesity, antiviral, antibiotics, oncology, immunology, and inflammation. He has contributed to multiple clinical compounds. Dr. Shen has more than 100 publications and over 80 patent applications, and has delivered over 100 invited lectures. He is currently a Fellow of the Royal Society of Chemistry (FRSC), and a lecturer at Shanghai Jiaotong University School of Pharmacy, Tsinghua University School of Pharmaceutical Sciences, and CCDRS, Peking University. Dr. Shen is also a mentor at ShanghaiTech University, a member of the Medicinal Chemistry Committee of Shanghai Pharmaceutical Association. He is a reviewer of 18 international journals and a scientific advisor of three journals/book series.
Xiujun Cai 蔡秀军
Sir Run Run Shaw Hospital, Zhejiang University, 浙江大学医学院附属邵逸夫医院
Xiujun Cai is the president of Sir Run Run Shaw Hospital of Zhejiang University and the director of both the Institute of Minimally Invasive Surgery of Zhejiang University and the Key Lab of Surgery of Zhejiang Province. He graduated from Zhejiang University School of Medicine in 1986 and got the PhD in 1992. Between 1994 and 1995, He had the fellowship in the West Virginia University Medical Center, USA.
Xiansheng Hua 华先胜
City Brain & VP, Artificial Intelligence Center, Alibaba, 阿里巴巴人工智能中心
He holds Ph.D. in Applied Mathematics from Peking University IEEE Fellow, ACM Distinguished Scientist, Leading authority in the field of visual identification and search. Served as the chairman of multiple committees for international conferences, including ACM Multimedia and IEEE ICME. Honored as a member of the MIT TR35.
Maode Lai 来茂徳
China Pharmaceutical University,中国药科大学
Professor Maode Lai graduated from the Department of Medicine of Zhejiang Medical University in 1982. He received his MS degree in medicine from Zhejiang Medical University in 1987 and his MD degree from Luebeck Medical University in Germany in 1990. He became professor in 1994. He has been adjunct professor of the University of Alberta in Canada since 2010. He was selected as a member of German National Academy of Sciences Leopoldina in 2011. He became vice-president of Zhejiang Medical University in 1996 and vice-president of Zhejiang University in 1998. He has been president of China Pharmaceutical University since 2013.
Edouard Nice
Monash University
Prof Ed Nice is currently an Adjunct Professor at Monash University where he is Head of Clinical Biomarker Discovery and Validation of Biochemistry and Molecular Biology) and a scientific advisor to the Monash Antibody Technologies Facility (MATF), for which he was director from 2009 - 2013. He also holds a Visiting Professorship at Sichuan University/West China Hospital and an Adjunct position at Macquarie University, Sydney, Australia. His long-term research interests have been in protein and peptide micropurification, biomarker discovery and validation, SPR analysis, high throughput monoclonal antibody production and validation, and clinical biomarker assay development, with a strong translational focus on colorectal cancer, especially the development of faecal proteomics.
Andrea Urbani
Università Cattolica del "Sacro Cuore"
Prof. Andrea Urbani started his research experience in 1990 within the Protein Biochemistry group of Prof. Federici (Tor Vergata University, Rome). During the PhD training (1994-1998) he has been working in the Merck, Sharp and Dohme laboratories of Pomezia (IRBM P. Angelini, Rome) on the functional and structural characterisation of the NS3 serine protease from the Hepatitis C Virus. This activity has led to the filing and extension of two patents application by MSD. Upon gaining the PhD title he moved to Heidelberg (Germany) at the European Molecular Biology Laboratory (EMBL) in the Structural Biology Programme (1998-2001) where he has pursued structural and functional investigation on integral membrane protein complexes. Following this experience he moved as a visiting scientist at the German Cancer Research Centre (Deutsches Krebsforschungszentrum) in the Analitycal Protein Chemistry unit where he has dedicated most of the investigations in the proteomics area. In his scientific experience he has been involved in protein characterisation by a number of different techniques. Mass spectrometry characterisation and identification of proteins represent the light motif of the laboratory he has developed during the last ten years. He has been the President of the Italian Proteomics Association (ItPA) years 2010-2015 and President of the European Proteomics Association (EuPA) for the years 2015-present. His international publication record is represented by over 200 contributions on journal with peer review system for a total impact factor above 600, his h-index is 40 based on approx. 5103 citations (SCOPUS, Elsevier, February 2019).
Stan Z. Li 李子青
Westlake Universisty, 西湖大学
He received his Ph.D. degree from Surrey University, UK, in 1991. He was awarded Honorary Doctorate of Oulu University, Finland, in 2013. He was the director of the Center for Biometrics and Security Research (CBSR) , Chinese Academy of Sciences, 2004~2019. He worked at Microsoft Research Asia as a Research Lead, 2000~2004. Prior to that, he was an associate professor (tenure) at Nanyang Technological University, Singapore. He joined Westlake University as a Chair Professor of Artificial Intelligence in February, 2019. His current interests include fundamental research in machine learning, data science, and applied research in multiple AI-related interdisciplinary fields (computer vision, smart sensors, life science, material science, and environmental science).
汪道文
Tongji Medical College, Huazhong University for Science & Technology
Dean of Department of Cardiology, TJH; Member of Chinese Society of Cardiology; Vice-President of Chinese Association of Cardiology in Hubei; Expert of National Cardiovascular Center, Ministry of Health; Standing Committee of Chinese Association of Pharmaceutical Biotechnology biological samples library Branch Member of American Heart Association, Member of International Society of Hypertension; Executive director of the Chinese Hypertension League Council; Expert in Expert Database of Hubei occupational health assessment; Member of second group of Hubei Medical Association Medical Malpractice Expert; Editorial Board of ISRN Cardiology; Editorial Board of Chinese Journal of Cardiovascular diseases; Associate Editor of Chinese Journal of Molecular Cardiology; Associate Editor of Journal of Internal Intensive Medicine; Editorial Board of Chinese Journal of Circulation; Editorial Board of Chinese Journal of Hypertension; Editorial Board of Journal of Clinical Cardiology and Journal of Clinical Internal Medicine; Editorial Board of Chinese Journal of Chinese Journal of Geriatric Heart Brain and Vessel Diseases; Reviewers of Regenerative Medicine, Gene Therapy, Stroke, Human Gene Therapy, Hypertension, JACC, Apoptosis, and other over ten kinds of journals.
Min Huang 黄敏
Thermo Fisher Scientific
Min Huang, PhD, current senior application engineer of life science mass spectrometry in Thermo Fisher Scientific, responsible for the technique development and application support of mass spectrometry related to proteomics and structural biology
Tiannan Guo 郭天南
Westlake Universisty, 西湖大学
Tiannan GUO, Ph.D. School of Life Sciences. Tiannan received training of clinical medicine (1999-2006) in Tongji Medical College, Huazhong University of Science and Technology, and learned biology (2001-2005) in Wuhan University, China, before he moved to Singapore for PhD training in cancer proteomics (2008-2012) in the laboratories of Dr. Newman Sze in Nanyang Technological University and Dr. Oi Lian Kon in National Cancer Centre Singapore. In 2012, Tiannan started his postdoctoral training in the laboratory of Dr. Ruedi Aebersold in ETH Zurich. Tiannan moved to Sydney as the Scientific Director of ProCan, group leader of Cancer Proteome, conjoint senior lecturer in Sydney Medical School, The University of Sydney, in March 2017. Tiannan joined the Westlake Institute for Advanced Studies in August 2017 as a Tenure Track Assistant Professor.
Opening
08:50-09:00 Beijing
19:50-20:00(-1) Boston
0:50-01:00 London
11:50-12:00 Sydney
01:50-02:00 Zürich
Introduction and Overview
Stephen Pennington (University College Dublin)
Fuchu He 贺福初 (National Center for Protein Sciences, Beijing)
Tiannan Guo 郭天南 (Westlake University)
Welcome from the president of Westlake University
09:00-09:10 Beijing
20:00-20:10(-1) Boston
01:00-01:10 London
12:00-12:10 Sydney
02:00-02:10 Zürich
Yigong Shi 施一公 (Westlake University)
Section A1: Proteomics for biomedical research and clinical medicine
Coordinators:
Ping Xu 徐平 ( National Center for Protein Sciences, Beijing)
Stan Z. Li 李子青 ( Westlake University)
Tiannan Guo 郭天南 (Westlake University)
09:10-09:26 Beijing
20:10-20:26(-1) Boston
01:10-01:26 London
12:10-12:26 Sydney
02:10-02:26 Zürich
蛋白质组学与肿瘤标志物的研究（结直肠癌）
Shu Zheng 郑树 (Zhejiang University)
郑树教授主要介绍了通过基因组学与蛋白质组学检测手段，对大肠癌患者的组织、血浆、血液中外泌体样本进行检测，揭示了结直肠癌发生发展过程中蛋白组和基因表达的变化，发现并验证了多个肿瘤标志物，为结直肠癌的早期诊断和精准治疗提供理论基础。
09:26-09:45 Beijing
20:26-20:45(-1) Boston
01:26-01:45 London
12:26-12:45 Sydney
02:26-02:45 Zürich
蛋白组学在感染性疾病的临床及基础研究中的应用
Lanjuan Li 李兰娟 (Zhejiang University)
09:45-10:08 Beijing
20:45-21:08(-1) Boston
01:45-02:08 London
12:45-13:08 Sydney
02:45-03:08 Zürich
PDPM: proteomics-driven precision medicine
Fuchu He 贺福初
Talking language: Chinese
Slide language: English
(National Center for Protein Sciences, Beijing)
10:08-10:23 Beijing
21:08-21:23(-1) Boston
02:08-02:23 London
13:08-13:23 Sydney
03:08-03:23 Zürich
How should prognostic and predictive biomarkers be evaluated?
Ruiping Xiao 肖瑞平
Talking language: English
Slide language: English
(Peking University & Associate Editor, NEJM)
Dr. Ruiping Xiao briefly introduce the history, the focuses and review processes of NEJM. Recently the they prefers creative medical breakthrough, and take 21-gene as a prognostic biomarker in breast cancer as an example. Finally, he summarized the talents and limits of the application of proteomics study in clinical researches, and also gave some corresponding solutions.
10:23-10:30 Beijing
21:23-21:30(-1) Boston
02:23-02:30 London
13:23-13:30 Sydney
03:23-03:30 Zürich
Questions, Recommendations and Conclusions
Section A2: Proteomics for biomedical research and clinical medicine
Coordinators:
Jimin Shao 邵吉民 (Zhejiang University)
Tiannan Guo 郭天南 (Westlake University)
10:30-10:46 Beijing
21:30-21:46(-1) Boston
02:30-02:46 London
13:30-13:46 Sydney
03:30-03:46 Zürich
Drug discovery and proteomics
Hong Shen 沈宏
Talking language: English
Slide language: English
(Roche Innovation Center Shanghai)
Mass spectrometry-based proteomics is a powerful technology to profile proteome and monitor protein communities in drug discovery. The applications in drug discovery demonstrate the impact of mass spectrometry-based proteomics in target and off-target identification, the understanding of PPI & biological pathways, time-, space- and dose-dependent signaling events mediated by PTMs, etc. Future directions could be to evaluate protein communities more often in vivo, to measure stoichiometry of proteins, and to provide methods for clinical samples.
10:46-11:05 Beijing
21:46-22:05(-1) Boston
02:46-03:05 London
13:46-14:05 Sydney
03:46-04:05 Zürich
蛋白质组学临床应用
Xiujun Cai 蔡秀军
Talking language: Chinese
Slide language: Chinese
(Sir Run Run Shaw Hospital, Zhejiang University)
11:05-11:25 Beijing
22:05-22:25(-1) Boston
03:05-03:25 London
14:05-14:25 Sydney
04:05-04:25 Zürich
Potential roles of proteomics in a City Brain
Xiansheng Hua 华先胜
Talking language: Chinese
Slide language: English
(City Brain & VP, Artificial Intelligence Center, Alibaba)
城市大脑对城市进行4维时空建模，需要Video, GPS，Coil，Bus等数据。城市大脑可以为医疗健康领域赋能。城市大脑和人体的循环系统（人体的运作）等有异曲同工之妙。可以利用大数据的技术对药物靶点进行优化（疫苗，抗原设计）。
11:25-11:45 Beijing
22:25-22:45(-1) Boston
03:25-03:45 London
14:25-14:45 Sydney
04:25-04:45 Zürich
COVID-19 and cardiac injury
Daowen Wang 汪道文
Talking language: English
Slide language: English
(Tongji Medical College, Huazhong University for Science & Technology)
In severe COVID-19 patients, the levels of heart biomarkers upregulate. Cardiac injure might cause by cytokine storm. RAAS inhibitors will increase ACE2 expression leading to the occur of Cardiac Injure?
11:45-11:57 Beijing
22:45-22:57(-1) Boston
03:45-03:57 London
14:45-14:57 Sydney
04:45-04:57 Zürich
Standardization and harmonization of multi-center proteotype analysis supporting translational studies
Min Huang 黄敏
Talking language: English
Slide language: English
(Thermo Fisher Scientific)
High resolution MS1-DIA workflow-digital biobank: the standardization method includes defined QC, optimized LC separation and efficient data acquisition. Tow kinds samples: QC samples (Commercial HeLa peptides) and controlled samples (mixture of HeLa, yeast and E.coli). several QC criteria for LC and MS performance: media LC peak, number of MS1, MS2 data points, precursor ID, proteins ID and inter-injection median CV of precursors.QC-standard: Three injections per day were needed. Inter-day and inter-lab reproducibility: over 80% of the total quantification proteins were quantified on each day or locally. Quantification accuracy and precision: the median values were lower than 10% deviation for human and yeast proteins and lower than 20% deviation for E.coli proteins. Median CV were lower 5% for the human and yeast proteins and 10% for E.coli. Application: Archival ovarian cancer tissue-clear cell and high grade serous, 5721 unique protein groups were identified from all tumor samples, 394 significantly dysregulation proteins between the two types of ovarian cancer samples. Use a streamlined HRMS1-DIA workflow to acquire data and analyze.Clinical Study: 5712 proteins were identified from all tumor samples, 394 significantly altered proteins between those two types of ovarian cancer samples.
11:57-12:20 Beijing
22:57-23:20(-1) Boston
03:57-04:20 London
14:57-15:20 Sydney
04:57-05:20 Zürich
Questions, Recommendations and Conclusions
Lunch Break
Section B: Proteomics and beyond
Coordinators:
Edouard Nice (Monash University)
Catherine Wong 黄超兰 (Peking University)
Tiannan Guo 郭天南 (Westlake University)
13:00-13:20 Beijing
00:00-00:20 Boston
05:00-05:20 London
16:00-16:20 Sydney
06:00-06:20 Zürich
Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression
Yu-Ju Chen
Talking language: English
Slide language: English
(Academia Sinica)
Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression Proteogenomics reveals signaling network of driver gene, such as EGFR, KRAS, which have been as effective drug targets.
In the genome level, East Asia is mainly induced by EGFR, while USA is mainly induced by KRAS mutation. The unmet clinical needs in late stage patients focus on seeking effective drug targets.
High quality specimens and analytical pipeline as the support.
In the early stage, higher APOBEC mutation signature in female with short survival but better response to immunotherapy.
The downstream of MAPK signaling cascade in EGFR-Mt/WT patient Protein network of proteomics for drug target
13:20-13:40 Beijing
00:20-00:40 Boston
05:20-05:40 London
16:20-16:40 Sydney
06:20-06:40 Zürich
基于代谢组学方法发现结直肠癌诊断标志物
Maode Lai 来茂德
Talking language: Chinese
Slide language: Chinese
(China Pharmaceutical University)
来茂德教授通过利用代谢组学手段，对健康/代谢综合征/结直肠癌人群的血清样本进行非靶向代谢组学检测，找到30个候选代谢物，进一步在1594个样本中进行进一步验证，最终得到7个潜在代谢物，并对其与临床参数相关性进行描绘。最终从7个代谢物简化到2个代谢物，并在独立队列中得以验证。本研究对结直肠癌诊断提供新方法新思路
13:40-14:00 Beijing
00:40-01:00 Boston
05:40-06:00 London
16:40-17:00 Sydney
06:40-07:00 Zürich
Metabolomics and precision medicine
Huiru Tang 唐惠儒
(Fudan University)
14:00-14:20 Beijing
01:00-01:20 Boston
06:00-06:20 London
17:00-17:20 Sydney
07:00-07:20 Zürich
AI for life sciences
Stan Z. Li 李子青
Talking language: English
Slide language: English
(Westlake University)
Prof. Li introduces how to study omic researches by AI based strategy. Firstly, introduce AI and proteomic strategies assist cancer diagnosis, then give an example: differential diagnosis of benign and malignant thyroid nodules. The type of thyroid nodules is able to diagnose by artificial neural network, meanwhile provide another method for classifying cancer type by proteomic profiling. Secondly, introduce a novel high-dimensional data analysis method, which is called Deep Manifold Transformation (DMT). Compared with t-SNE and UMAP, the results demonstrated DMT is much better in many aspects, such as dimensionality reduction, clustering, visualization and so on. As far as possible, the global structure and serial characteristics of data are guaranteed in the low dimensional space and have good application results in single cell data.
14:20-14:30 Beijing
01:20-01:30 Boston
06:20-06:30 London
17:20-17:30 Sydney
07:20-07:30 Zürich
Questions, Recommendations and Conclusions
14:30-15:00 Beijing
01:30-02:00 Boston
06:30-07:00 London
17:30-18:00 Sydney
07:30-08:00 Zürich
Tea break
Section C1: Emerging proteomics technologies
Coordinators:
Stephen Pennington (University College Dublin)
Yu-Ju Chen (Academia Sinica)
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
15:00-15:45 Beijing
02:00-02:45 Boston
07:00-07:45 London
18:00-18:45 Sydney
08:00-08:45 Zürich
Technology and applications of MS-based proteomics to body fluid and tissue analysis
Matthias Mann (Max Planck Institute)
These years they focus more on clinical applications than cellular biology, and that’s what the following 5 parts (technology, PTM, plasma proteome profiling，single cell proteomics and deep visual proteomics) will be related with.
Technology (Introduction of two software and one hardware)
AlphaPept Framework: --a super-fast framework for the analysis of MS-based proteomics--open source, codebase by python and UI solution for non-experts--Python combined with Numba package make the analysis ultrafast the Clinical Knowledge Graph (CKG)--integrates proteomics data into clinical decision-making--Open source tool for data integration, analysis (the latest statistical and machine learning algorithms included) and interpretation (based on relevant experimental data, public databases and the literature)
Trapped ion mobility spectrometry (TIMS)--Ion mobility separation Parallel Accumulation – Serial Fragmentation (PASEF)
--Increased signal-to-noise by signal compression
--Full precursor mass resolution
--Multiplied sensitivity and sequencing speed
--diaPASEF could be more robust for future clinical proteomics
Post-translational modifications
(LRRK2 in Parkinson’s disease)
Method: Phosphoproteomics simplified protocol EasyPhos
Application: hunt for substrates of multidomain Leucine-rich repeat kinase 2 (LRRK2)
--genetic cause of Parkinson’s disease: pathogenic mutations of LRRK2.
--G2019S substitution on LRRK2 protein activates the kinase
--genetics (cells from genetically modified mice), pharmacology (selective LRRK2 inhibitors), phosphoproteomics (EasyPhos, 27,000 phosphosites on ~6000 proteins)
--Rab10 and Rab12 are phosphorylated by LRRK2
Plasma proteome profiling (liver disease)
Application: diagnostic tool for early detection of liver disease
Study 1: plasma proteomics identified novel proteins associated with non-alcoholic fatty liver disease (NAFLD)
--plasma proteome of 3 matched sub-cohorts by BoxCar acquisition
--in cirrhotic liver, 77% downregulated plasma proteins are “liver-specific”
--six proteins significantly associated with NAFLD
--global correlation of plasma proteins and clinical parameters (liver enzymes)
--In HFD-induced NAFLD mouse model, identified maker candidates in human cohort recapitulated similar changes, providing evidence that these proteins may be good biomarkers.
Study 2: proteomics identified circulating protein markers for alcohol-related liver disease (ALD)
--a paired plasma (N=596) and liver tissue (N=79) proteome profiling
--of the 407 overlapped proteins between liver and plasma, 91 had significant correlations
--52 co-regulated proteins in the plasma and liver display distinct temporal patterns across fibrosis stages.
--machine learning models based on plasma proteome to predict early-stage of fibrosis, inflammation and steatosis, which outperform existing tests
Single cell proteomics
In EvoTip single cell processing and Evosep liquid chromatography for ultra high-sensitivity single cell proteomics.
~1000 protein groups identified with high quantitative reproducibility at the single cell level (Hela cell line).
Deep visual proteomics
Workflow: High-parametric images with subcellular resolution of archived patient tissue samples – image segmentation with deep learning training – machine learning algorithms to predict cellular phenotypes – single-cell isolation (including with subcellular spatial resolution or other arbitrary structures) using laser capture microdissection – cell type specific proteomes – Clinical Knowledge Graph – resource for researchers and clinicians
15:45-16:30 Beijing
02:45-03:30 Boston
07:45-08:30 London
18:45-19:30 Sydney
08:45-09:30 Zürich
The modular proteome and its clinical significance
Ruedi Aebersold (ETH Zurich)
Ruedi tried to find out how alterations in the molecular constellation determines alterations in function/phenotype from three aspects.
1. How does genomic variability affect proteotype composition and phenotype? Method:Multi-layer molecular profiles for Hela cells with different phenotypes (e.g. doubling time and the ability to be infected)Effect of genomic variability on molecular profiles and phenotypes was calculated. Conclusion: Genotypic variability propagates along the axis of the central dogma in poorly predictable ways.Organization of proteins into complexes acts as a significant buffer of genotype variability.
2. How does genomic variability affect proteotype organization and deterministic functions? Method: Size exclusion chromatography mass spectrometry (SEC-MS) and size exclusion chromatography algorithmic toolkit (SECAT) Compute effect of genotypic variation on protein complexes and protein interaction networks. Results: Genomic variability affects the proteotype organization at the level of complexes and PPIs. Conclusion: New MS method and algorithms enable us to relate function to phenotype.
3.How can we predict altered proteotype modules and deterministic functions from transcript or protein profiles? Method: Proteome abundance profiles by SWATH/DIA Evaluation of changes in modularity based on changes in co-expression covariance and observing different deterministic functions, they tried to find out the relationship between these features. Conclusion: Proteins in the same complex (e.g. ATP synthase subunit alpha) tend to correlate across different samples. Different stage of prostate cancers exhibit altered quantitative relationships in many protein pairs. Genomic variants can alter specific protein modules and thus their function.
16:30-16:45 Beijing
03:30-03:45 Boston
08:30-08:45 London
19:30-19:45 Sydney
09:30-09:45 Zürich
Mattias Q&A
16:45-17:00 Beijing
03:45-04:00 Boston
08:45-09:00 London
19:45-20:00 Sydney
09:45-10:00 Zürich
Ruedi Q&A
Section C2: Emerging proteomics technologies
Coordinators:
Yu-Ju Chen (Academia Sinica)
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
17:25-17:50 Beijing
04:25-04:50 Boston
09:25-09:50 London
20:25-20:50 Sydney
10:25-10:50 Zürich
Technologies for high-throughput clinical proteomics
Bernhard Küster (Technische Universität Muenchen)
Benhard develops MS-based technologies for high-throughput at high quality.
1, analysis of body fluids and whole proteomes by micro-LD MS/MS.The 50 uL/min LC flow generates stable performances while high quality. Data from 1500 consecutive injections showed high retention time consistence. It was also applied to analyzed the phosphoproteomes of 377 cancer cell line and quantified 12,700 proteins in total and 12000 p-sites.
2, analysis of FFPE material by single-shot LC-FAIMS-MS/MS.The optimized workflow also generates high ids (~30,000 peptides) per shot with low CVs.
3, Prosit prediction of spectral libraries and re-scoring of LC-MS/MS data.The great effort made on Prosit establishment can predict fragment patterns and retention time with high precision, and is currently serving the scientific community very well.
17:50-18:15 Beijing
04:50-05:15 Boston
09:50-10:15 London
20:50-21:15 Sydney
10:50-11:15 Zürich
Clinical proteomics in interesting times
Roman Fischer (University of Oxford)
18:40-19:02 Beijing
05:40-06:02 Boston
10:40-11:02 London
21:40-22:02 Sydney
11:40-12:02 Zürich
Single cell proteomics (SCP): glass-Oil-Air-Droplet (gOAD) pico chip
Catherine Wong (Peking University)
19:02-19:10 Beijing
06:02-06:10 Boston
11:02-11:10 London
22:02-22:10 Sydney
12:02-12:10 Zürich
Dinner break
Section D: Industrialized proteomics for the clinic
Coordinators:
Stephen Pennington (University College Dublin)
Yu-Ju Chen (Academia Sinica)
Andrea Urbani (Università Cattolica del "Sacro Cuore")
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
20:00-20:17 Beijing
07:00-07:17 Boston
12:00-12:17 London
23:00-23:17 Sydney
13:00-13:17 Zürich
Development of a pipeline for biomarker discovery using proteomics
Anthony Whetton (The University of Manchester)
Introduce the concept of precision medicine and genomic/proteomic applications in precision medicine nowadays. Further explain why we need to discover biomarkers; the reason is that individuals have differential responses for the same drugs or therapies. Briefly introduce Stoller Biomarker Discovery Center in Manchester and industrializing clinical proteomic strategies. Anthony focuses on SWATH-MS based plasma proteomics and gives some examples used industrializing clinical proteomic strategies: 1) grey platelet syndrome 2) chronic kidney disease. UK Biobank has had genomic data and its proteomic analysis of plasma/urine/mixed saliva is planned now.
20:17-20:40 Beijing
07:17-08:40 Boston
12:17-12:40 London
23:17-00:40(+1) Sydney
13:17-13:40 Zürich
Procan-adapting proteomics for the cancer clinic
Roger Reddel (The University of Sydney)
20:40-21:00 Beijing
07:40-09:00 Boston
12:40-13:00 London
23:40-01:00(+1) Sydney
13:40-14:00 Zürich
Break
Section E: Translational proteomics
Coordinators:
Stephen Pennington (University College Dublin)
Yu-Ju Chen (Academia Sinica)
Jun Qin (National Center for Protein Sciences, Beijing)
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
21:00-21:30 Beijing
08:00-08:30 Boston
13:00-13:30 London
00:00-00:30(+1) Sydney
14:00-14:30 Zürich
Translation of protein biomarkers: It’s simple
Stephen Pennington (University College Dublin)
New protein biomarkers will be complimentary to genomics to promote precision medicine. The protein biomarker pipeline includes discovery, confirmation assay development, evaluation/validation and approval/adoption. The sample amounts and detection methods for each stage are different. The authors suggested the application of MRM in the confirmation and evaluation stages.
Dr. Pennington presented one of his study about developing blood biomarkers for discriminate patients with psoriatic arthritis (PsA) and Rheumatoid Arthritis (RA). Before that, there were no criteria to distinguish PsA form RA or other arthropathies. After comparing the serum proteomic profiles between PsA and RA patients using MS-based labeled proteomics, SOMAscan and Luminex, they found some unbiased biomarker candidates. They further supplement the biomarker candidates with existing panel and literature to make a panel called PAPRICA containing ~200 proteins and >400 peptides for the following MRM analysis. They have tested the panel on a new cohort containing 169 patients and achieved an AUC of 0.9 using normalized MS data. They ‘ll further evaluate the panel in a larger cohort containing 1000 patients
21:30-21:48 Beijing
08:30-08:48 Boston
13:30-13:48 London
00:30-00:48(+1) Sydney
14:30-14:48 Zürich
Psychiatric disorder pathway illumination using omics
Chris W. Turck (Max Planck Institute of Psychiatry)
Psychiatric disorders have a great effect on the physical health of modern people. The diagnosis of psychiatric disorders is difficult using barely the clinical determined factors or indicators. People have been applying omics technologies to study psychiatric disorders, and comparing with the results of genomic characterization, the results of proteome/metabolome/microbiome characterization vary from day to day, herein could better reflect the psychiatric conditions, feasible for this type of study. In Psychiatric disorder biomarker study, animal models and body fluid from patients can be the substitutes for the human brain tissue because of their easy access.
To study the biosignatures of anxiety disorder, Dr. Turck and his team created the stress susceptible DBA/2NCrl and C57BL/6NCrl mice and performed transcriptomic proteomic analysis of the brain tissue of susceptible mice. They found:
1) opposite regulation of the same mitochondria related genes in DBA/2NCrl and C57BL/6NCrl stress susceptible mice, which indicated the gene background affects the stress-induced behaviors
2) blood gene expression of mitochondria related genes in panic disorder patients resembles DBA/2NCrl stress susceptible mice but in lower intensity
Dr. Turck demonstrated the alterations of mitochondria related genes in anxiety and panic disorder, and further stated that these studies are still far from clinical insights.
22:15-22:40 Beijing
09:15-09:40 Boston
14:15-14:40 London
01:15-01:40(+1) Sydney
15:15-15:40 Zürich
Questions, Recommendations and Conclusions
Concluding remarks
22:40-23:00 Beijing
09:40-10:00 Boston
14:40-15:00 London
01:40-02:00(+1) Sydney
15:40-16:00, Zürich
Tiannan Guo 郭天南 (Westlake University)
Matthias Mann (Max Planck Institute)
Jun Qin 秦钧 (National Center for Protein Sciences, Beijing)
Edouard Nice (Monash University)
Stephen Pennington (University College Dublin)
Acknowledgements
Progresses and Perspectives of Mass Spectrometry-based Clinical Proteomics
基于质谱的临床蛋白质组学的研究进展与展望
Co-chairs: Stephen Pennington, Fuchu He and Tiannan Guo
Supported by Westlake University, CNHUPO, HUPO
When: 04 Dec, 2020, 09:00-23:00 (UTC+8)
Where: Playbacks
Summary
The rapidly developing mass spectrometry-based proteomics is indispensable for precision medicine. However, its penetration into clinic has yet to prevail. One technical bottleneck is high throughput proteomic analysis of clinical specimens from (multi-center) cohort studies, whereas integrative analysis of proteomics data with clinical and other omics data poses another technical challenge. Moreover, the comprehension of the unmet clinical needs by the mass spectrometrists, and the understanding of the progresses and limitations of cutting-edge proteomic techniques by the clinicians are non-trivial. This symposium gathers experts from clinical medicine, proteomics and beyond, with a goal of building a complete picture of the MS-based clinical proteomics: the current status and the perspective for future development.
28
Speakers
10
Coordinators
2671
Online Participants
14.5
Hours
Yigong Shi 施一公
Westlake Universisty, 西湖大学
Ph.D.Principal Investigator, School of Life Sciences, Structural biology of cancer, with a focus on key regulatory components in the apoptotic pathways and other important cellular processe. Structural biology of important membrane proteins.Structural mechanisms of macromolecular machineries.
Ruedi Aebersold
ETH Zurich, Switzerland
Ruedi Aebersold is a Swiss and Canadian scientist trained at the Biocenter, University of Basel. He completed his Postdoctoral training at Caltech. He is a Professor at ETH Zurich and the University of Zurich. He was on the faculties of the Universities of British Columbia and Washington and co-founded, with Lee Hood and Alan Aderem, the Institute for Systems Biology in Seattle. He is on the SAB of a number of research organizations and has served as senior editor for Molecular and Cellular Proteomics and Molecular Systems Biology. He was elected as EMBO member in 2006.The research focus of his group is the proteome. The group has pioneered several widely used techniques and generated a range of open access/open source software and statistical tools that have contributed to making proteomic research results more transparent and accurate. The work has been recognized with numerous awards and prizes. More than 40 trainees of the group have reached faculty status at leading research institutions worldwide.
Fuchu He 贺福初
National Center for Protein Sciences, Beijing, 国家蛋白质科学中心（北京）
Dr. He is the leading scientist studying proteomics in China. He was the founder of CNHUPO and among the first group of people who founded HUPO in 2001. He was the first Chinese scientist who led an international consortium-Human Liver Proteome Project (HLPP), and the founder of Beijing Proteome Research Center, Phoenix Center (proteomics) and Institutes of Biomedical Sciences Fudan University. As the chief scientist, he has been propelling HLPP to the China Human Proteome Project (CNHPP), to create an encyclopedia of proteins in the human body under physiological and pathological conditions. Recently, his team stratified early hepatocarcinoma (HCC) into 3 proteomic subtypes with different clinical outcome. Some drug targetable proteins have been demonstrated useful in identifying patients with HCC who could potentially benefit from targeted treatment in further clinical trials. These studies demonstrated the proteomic analysis as an independent powerful tool in cancer molecular subtyping, indicating that the era of “Proteome Driven Precision Medicine (PDPM)” is coming.
Matthias Mann
Max Planck Institute, Germany
Matthias Mann studied physics and mathematics at Göttingen University and obtained his Ph.D. in chemical engineering at Yale, contributing to the Nobel Prize for his supervisor John Fenn for electrospray ionization. Since 2005 he is director at the Max Planck Institute of Biochemistry, Munich and since 2009 also director of the Department of Proteomics, Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen. He has obtained numerous prizes and is one of the most cited scientists with an h-factor of 232 and 250,000 total citations (Google Scholar). His work in sample preparation, chromatography, mass spectrometry and computer algorithms has been decisive in making mass spectrometry applicable to molecular biology. Apart from proteomics technology development his team works on fundamental cell and systems biological questions. Today they focus on clinically relevant topics, especially the analysis of the blood plasma proteome and cancer tissues at the single cell level.
Jun Qin 秦钧
National Center for Protein Sciences, Beijing, 国家蛋白质科学中心（北京）
Jun Qin is among the few people in the world, who can integrate MS instrument design, proteomic method development, bioinformatics, biology and clinical applications into one research program.
Bernhard Küster
Technische Universität Muenchen, Germany
Chair of Proteomics and Bioanalytics Technical University of Munich.Bernhard Kuster is a chemist by training and obtained is PhD in Biochemistry from the University of Oxford. He went on to do a PostDoc funded by an EMBO long-term fellowship at the EMBL in Heidelberg and the University of Southern Denmark in Odense. After seven years as VP Analytical Sciences and Informatics at the biotech firm Cellzome (now GSK), he became full professor of Proteomics at the Technical University of Munich in 2007. Bernhard currently serves as Vice Dean Information Management of the TUM School of Life Sciences, is the Director of the Bavarian Biomolecular Mass Spectrometry Center and a Carl von Linde Senior Fellow of the TUM Institute for Advanced Study. Bernhard’s research focuses on mass spectrometry based proteomics and its application to chemical and systems biology. He is particularly interested in i) which genes of an organism exist as proteins, where they are expressed and in which quantities, ii) how drugs interact with proteins, signaling pathways and cellular systems in order to understand their often multiple modes of action and iii) developing methods and tools to study proteomes. Bernhard has published over 200 papers on proteomics and bioinformatics that have been cited >30,000 times.
Catherine Wong 黄超兰
Peking University, 北京大学
Director, Center for Precision Medicine Multi-Omics Research, Peking University Health Science Center. Principal Investigator, Center for Life Sciences, Peking Unversity & Tsinghua University Associate Professor with Tenure, School of Basic Medical Sciences, Peking University Health Science Center Principal Investigator, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center Honorary Professorship, Faculty of Biology, Medicine and Health, The University of Manchester The Introduction of Outstanding Talents for Technology, Chinese Academy of Sciences Committee Member of Center for Transformation of Scientific and Technological Achievements, Peking University Health Science Center Committee Member of Protein Society, The Chinese Society of Biochemistry and Molecular Biology Chairman Member of Committee of Experimental Medicine (Mass Spectrometry), National Association of Health Industry and Enterprise Management Committee Member of China Human Proteome Organisation
Markus Ralser
Charite University Medicine, Germany
Markus Ralser (*1980), Prof. Dr Mag, Einstein Professor of Biochemistry, is Head of the Dept. of Biochemistry at the Charitè University Medicine (the joint medical faculty of Humboldt and Free state Universities in Berlin, Germany) while being a Senior Group Leader at the Francis Crick Institute (London).Previously, he was a Group leader at the Department of Biochemistry, University of Cambridge, a positionhe took after being trained in mass spectrometry at VU Amsterdam (Netherlands), and being a Junior group at the Max Planck Institute for Molecular Genetics (Berlin). The Ralser lab is known for fundamental discoveries that have improved our understanding of how cells can coordinate hundreds of biochemical reactions assembled in the metabolic network, and for the development of high-throughput mass spectrometry technologies. Major publications from the Ralser lab have linked each yeast gene to its role in metabolism, have shown that metabolism is much more flexible and integrated into the physiology of cells as it was expected only a few years ago. Moreover, results obtained in the Ralser lab have provided fundamental insights on how central carbon metabolism could have evolved in early life forms, how reactions can co-occur within a cell despite competing chemistries, and how yeast and cancer cells reconfigure metabolism to be protected against oxidative stress. The Ralser lab is/has been the recipient of substantial funding by The Crick, the Wellcome Trust, the ERC, EMBO, the BMBF (Germany), the Max Planck Society and the BBSRC. He was selected into the EMBO Young investigator programme, he is a Wellcome Trust Beit fellow, and he is a recipient of the 2008 BioMed central Research Award, the 2017 Colworth Medal of the Biochemical Society, the 2019 Starling Medal of the Endocrinological Society. and the 2020 EMBO Gold medal.
Lanjuan Li 李兰娟
Zhejiang University, 浙江大学
Professor Lanjuan Li is a member of Chinese Academy of Engineering, and Professor/Chief Physician of Infectious Diseases, the 1st Affiliated Hospital, Zhejiang University. She also serves as the director of the State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Diagnosis and Treatment, the director of Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases. She has been engaged in clinical, teaching and research work of infectious diseases for about 40 years and served as editor-in-chief for 33 books, publishing more than 400 high-level international peer-reviewed articles (including Nature, Lancet and New England Journal of Medicine).
Shu Zheng 郑树
Zhejiang University, 浙江大学
The professor of Medicine department of Zhejiang University, and doctoral supervisor·The deputy director of the Development Committee of Zhejiang University·Director of the Cancer Institute Academic Committee of Zhejiang University=·Vice president of Chinese Anti-Cancer Association·Chairman of the Professional Committee of the National Colorectal Cancer·Executive director of the Chinese Medical Association
Yu-Ju, Chen
Academia Sinica
B.S., 1992, National Taiwan University. Ph.D., 1997, Iowa State University. Postdoctoral Research Fellow, 1997, Ames Laboratory; 1998-1999, National Tsing-Hua University. Assistant Research Fellow, 1999-2005; Associate Research Fellow, 2005-2010; Research Fellow, 2010-2019; Distinguished Research Fellow, 2019-present; Director, 2013-2019, Institute of Chemistry; Acting Director, 2019-present, Institute of Chemistry; Adjunct Research Fellow, 2004-present, Genomic Research Center, Academia Sinica. President, 2009-2011, Taiwan Proteomics Society. Editorial Board Member, 2008-present, European Journal of Mass Spectrometry. Council Member, 2009-present, AOHUPO.
Ruiping Xiao 肖瑞平
Peking University, NEJM
Dr. Xiao has made important discoveries in beta-adrenergic receptor (AR) subtype signaling, with an emphasis on translating bench discoveries to the bedside. She was the first to show that beta2-AR dually couples to Gs and Gi, revealing a new signaling paradigm of the G protein-coupled receptor superfamily. While chronic beta1-AR stimulation causes heart cell death and cardiomyopathy by Ca2+/calmodulin kinase II-dependent pathways, beta2-AR is cardiac protective. She co-invented the Gs-biased, chiral beta2-AR agonist R,R-feneterol and co-supervised its Phase I clinical trial (Phase II planned), spearheading a novel therapy treating heart failure with beta2-AR agonist R,R-feneterol or derivatives combined with beta1-AR blocker. Her current research has revealed that MG53 E3 ligase-mediated, ubiquitin-dependent degradation of insulin receptor and insulin receptor substrate 1 constitutes a fundamental mechanism for the development of systemic insulin resistance, leading to the sequelae of metabolic syndrome and cardiovascular complications. She has authored >140 peer-reviewed publications. She has been global leader in biomedical research and served as the founding director of the Institute of Molecular Medicine, Peking University since 2005. She has also played a leadership role in clinical translational research and currently serves as an Associate Editor of The New England Journal of Medicine。
Stephen Pennington
University College Dublin
Steve is currently Professor of Proteomics at the UCD School of Medicine & Conway Institute in Dublin, Ireland. He graduated from Imperial College of Science and Technology (Imperial College London) with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge. Steve and his research team are actively engaged in a number of collaborative proteomics projects focussed on comprehensive proteomics scale analysis of protein expression and function to support improved understanding of mechanisms of disease progression and diagnosis. They are currently focussed on the development of multiplexed protein biomarker measurements using multiple reaction monitoring mass spectrometry to support the translation of novel multiplexed blood protein biomarkers to clinical diagnostic tests.
Ruijun Tian 田瑞军
Southern University of Science and Technology, 南方科技大学
Dr. Ruijun Tian obtained his Ph.D. in analytical chemistry from Dalian Institute of Chemical Physics, Chinese Academy of Sciences in 2008 (Mentor: Dr. Hanfa Zou). He then moved to Canada for his postdoctoral training with Dr. Daniel Figeys at Ottawa Institute of Systems Biology, University of Ottawa (2008-2010) and Dr. Tony Pawson at Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and University of Toronto (2010-2014). He joined Department of Chemistry, Southern University of Science and Technology (SUSTech) in 2014 as an associate professor and was promoted as tenured full professor in 2020. He is also adjunct professor of School of Medicine, University of Ottawa and Shenzhen People’s hospital. His major research interest is precision medicine-oriented MS-based proteomics technology development and applications mainly in intercellular signaling of tumor microenvironment. He has published more than 70 research papers in Nature, PNAS, Angew Chem., Mol. Cell. Proteomics, Anal. Chem., etc. with H-index of 27 (Google Scholar). He received 2012 Young Investigator Award from International Association for Protein Structure Analysis and Proteomics (IAPSAP), Canadian Institutes of Health Research (CIHR) postdoctoral fellowship, and President’s Scholarship from Chinese Academy of Sciences. He was the co-chairs for 2nd Young Investigator Symposium of CNHUPO and 5th China-Canada Systems Biology Symposium. He is the editorial board member for Chinese Journal of Chromatography (Young pannel) and Frontiers in Endocrinology.
Chris W. Turck
Max Planck Institute of Psychiatry, Munich, Germany
Prof. Chris Turck is Head of Proteomics and Biomarkers at the Max Planck Institute of Psychiatry. He also holds faculty appointments in the Department of Biochemistry at the University of Munich, International Max Planck Research School of Molecular and Cellular Life Sciences. International Max Planck Research School of Translational Psychiatry and Graduate School of Systemic Neurosciences. After receiving his Ph.D. degree in Chemistry he carried out postdoctoral work at the Roche Institute of Molecular Biology. Subsequently he was recruited to the Faculty of Medicine at the University of California, San Francisco where he was Director of the Howard Hughes Medical Institute Protein Structure Laboratory and Associate Investigator at the Cardiovascular Research Institute. Prof. Turck serves on the ‘Neuroscience Steering Committee’ of the fNIH Biomarkers Consortium and is chair of the ABRF Metabolomics Research Group. He recently received President’s International Fellowship Initiative funding from the Chinese Academy of Sciences for a collaboration with the Kunming Institute of Zoology. His research efforts center on the identification of biosignatures for psychiatric disorders and the antidepressant drug response using -omics technologies to delineate affected molecular pathways. The goal is to complement imprecise clinical parameters with molecular biosignatures to improve patient diagnosis, stratification and treatment. https://www.psych.mpg.de/1495985/turck
Huiru Tang 唐惠儒
Fudan University, 复旦大学
Huiru Tang Professor, Biochemistry and Molecular Biology, Fudan University. Winner of National Outstanding Youth Science Foundation. He received a bachelor's degree from Northwestern Light Industry College (now Shaanxi University of Science and Technology) in 1986 and a doctorate from London University in 1994. From 1992 to 2000, he successively served as Research Scientist, Senior Research Scientist at BBSRC Food Research Institute. From 2001 to 2005, he served as Senior Scientist in Biochemistry Department of Biomedical Engineering, Imperial College London. From 2005 to 2014, he successively served as researcher and doctoral supervisor of Wuhan Institute of Physics and Mathematics, deputy director of research department and director of Key Laboratory of Biological Magnetic Resonance Analysis of Chinese Academy of Sciences. November 2014 Fudan University Distinguished Professor.
Roman Fischer
University of Oxford
Roman Fischer is an Associate Professor and Senior Group Leader in Clinical Proteomics at the University of Oxford. He leads the Discovery Proteomics Facility at the Target Discovery Institute. RF studied Biotechnology at the Technical University Braunschweig and obtained his PhD at the Helmholtz Centre for Infection Research for the analysis of host-pathogen interactions of Listeria monocytogenes using proteomic methods (2007). After postdoctoral studies on Il-1 signalling in the laboratory of Professor Sir Philip Cohen in Dundee (Scotland), RF started to develop clinical proteomics at the University of Oxford in 2009. Since 2013 RF leads the Discovery Proteomics Facility and applies proteomic methods to a multitude of scientific questions. Currently, RF focusses his research on the development of high-throughput and spatial proteomics methods and their application to large clinical cohorts and specimen.
Roger Reddel
The University of Sydney
Professor Roger Reddel is a medical oncologist, molecular geneticist and an internationally renowned expert on cancer cell immortalisation. He is Director of Children’s Medical Research Institute (CMRI), Westmead, a Fellow of the Australian Academy of Science, and a Fellow of the Australian Academy of Health and Medical Sciences. His research career on the cellular and molecular biology of immortalisation commenced as a postdoctoral scientist (Fulbright Fellow) at the National Cancer Institute, Maryland, USA, where he improved techniques for immortalisation of human cells in vitro and made the key finding that immortalisation is necessary for malignant transformation of human cells. He returned to Australia to establish and head the Cancer Research Unit at CMRI, with a fellowship from Cancer Council NSW, which has provided major support ever since. He is internationally recognised for research on the enzyme telomerase and for discovering ALT (Alternative Lengthening of Telomeres), which together contribute to unlimited growth in >95% of cancers. His team has made additional seminal findings regarding ALT and the manner in which it is repressed in normal (non-cancer) cells, and identified a molecular marker for ALT. Overall his research aims to help develop anti-cancer treatments that would work by blocking immortalisation, and tests for detecting signs of cellular immortalisation for early detection of cancer. Professor Reddel has won numerous awards including the Ramaciotti Medal for Excellence in Biomedical Research (2007), the 2011 NSW Premier's Award for Outstanding Cancer Researcher of the Year, and the Neil Hamilton Fairley Medal of the Royal Australasian College of Physicians (2017). He was a founding member of the University of Sydney's Cancer Research Network and chaired its Translational Research Committee. He is a member of the Board of Paediatrio, which has been set up to coordinate paediatric research in NSW.
Ping Xu 徐平
National Center for Protein Sciences, Beijing, 国家蛋白质科学中心（北京）
Dr. Xu is interested in studying novel biological functions of ubiquitin chains and regulation of protein ubiquitination in the occurrence and development of liver disease by proteomics approaches. His research involves state-of-art technologies for profiling thousands of proteins and posttranslational modifications by quantitative mass spectrometry and large scale data processing.
Anthony Whetton
University of Manchester
New systems biology approaches will transform biomedical research. One key strand of this new approach is proteomics/mass spectrometry. He has worked effectively with clinical colleagues in the field of haematology for many years. However, his interactions now encompass research into many other malignancies and, for example, diseases of pregnancy and the lungs, due to the development of an “outstanding” (metrics: LLR international panel who site visited in 2013) mass spectrometry/proteomics facility. He advises internationally leading clinician scientists/bioscientists on the use of mass spectrometry and proteomics in their research. This is essential; too often these complex systems biology approaches lead to failure because of poor experimental design and/or lack of awareness of the technique’s limitations. The development of new biomarkers and surrogate endpoint markers is a key requirement for clinical trials and closing the translational gap in medicine. The establishment of a platform for biomarker discovery and validation from biological fluids (more generally available than biopsy material) has been a growing theme of my research.
Jimin Shao 邵吉民
Zhejiang University, 浙江大学
Professor and Chair, Department of Pathology and Pathophysiology.Executive Director, Center for Cancer Research,Associate Dean, School of Basic Medical Sciences, Zhejiang University. Research: (1)Cancer-promoting inflammation and cancer stem cell plasticity. (2)Neoantigens identification and technology development for cancer immunotherapy. (3)Protein structure and function of anti-cancer therapeutic targets and novel drug discovery.
Hong Shen 沈宏
Roche Innovation Center Shanghai, 上海罗氏创新中心
Dr. Hong Shen received his B.S. from Peking University and Ph.D. from Stanford University. After 9 years working at Merck in the US, he joined Roche Innovation Center Shanghai (RICS) in 2012. Dr. Shen is now the Site Head of RICS. Dr. Shen’s experience in drug discovery includes the areas of hypertension, diabetes, thrombosis, atherosclerosis, obesity, antiviral, antibiotics, oncology, immunology, and inflammation. He has contributed to multiple clinical compounds. Dr. Shen has more than 100 publications and over 80 patent applications, and has delivered over 100 invited lectures. He is currently a Fellow of the Royal Society of Chemistry (FRSC), and a lecturer at Shanghai Jiaotong University School of Pharmacy, Tsinghua University School of Pharmaceutical Sciences, and CCDRS, Peking University. Dr. Shen is also a mentor at ShanghaiTech University, a member of the Medicinal Chemistry Committee of Shanghai Pharmaceutical Association. He is a reviewer of 18 international journals and a scientific advisor of three journals/book series.
Xiujun Cai 蔡秀军
Sir Run Run Shaw Hospital, Zhejiang University, 浙江大学医学院附属邵逸夫医院
Xiujun Cai is the president of Sir Run Run Shaw Hospital of Zhejiang University and the director of both the Institute of Minimally Invasive Surgery of Zhejiang University and the Key Lab of Surgery of Zhejiang Province. He graduated from Zhejiang University School of Medicine in 1986 and got the PhD in 1992. Between 1994 and 1995, He had the fellowship in the West Virginia University Medical Center, USA.
Xiansheng Hua 华先胜
City Brain & VP, Artificial Intelligence Center, Alibaba, 阿里巴巴人工智能中心
He holds Ph.D. in Applied Mathematics from Peking University IEEE Fellow, ACM Distinguished Scientist, Leading authority in the field of visual identification and search. Served as the chairman of multiple committees for international conferences, including ACM Multimedia and IEEE ICME. Honored as a member of the MIT TR35.
Maode Lai 来茂徳
China Pharmaceutical University,中国药科大学
Professor Maode Lai graduated from the Department of Medicine of Zhejiang Medical University in 1982. He received his MS degree in medicine from Zhejiang Medical University in 1987 and his MD degree from Luebeck Medical University in Germany in 1990. He became professor in 1994. He has been adjunct professor of the University of Alberta in Canada since 2010. He was selected as a member of German National Academy of Sciences Leopoldina in 2011. He became vice-president of Zhejiang Medical University in 1996 and vice-president of Zhejiang University in 1998. He has been president of China Pharmaceutical University since 2013.
Edouard Nice
Monash University
Prof Ed Nice is currently an Adjunct Professor at Monash University where he is Head of Clinical Biomarker Discovery and Validation of Biochemistry and Molecular Biology) and a scientific advisor to the Monash Antibody Technologies Facility (MATF), for which he was director from 2009 - 2013. He also holds a Visiting Professorship at Sichuan University/West China Hospital and an Adjunct position at Macquarie University, Sydney, Australia. His long-term research interests have been in protein and peptide micropurification, biomarker discovery and validation, SPR analysis, high throughput monoclonal antibody production and validation, and clinical biomarker assay development, with a strong translational focus on colorectal cancer, especially the development of faecal proteomics.
Andrea Urbani
Università Cattolica del "Sacro Cuore"
Prof. Andrea Urbani started his research experience in 1990 within the Protein Biochemistry group of Prof. Federici (Tor Vergata University, Rome). During the PhD training (1994-1998) he has been working in the Merck, Sharp and Dohme laboratories of Pomezia (IRBM P. Angelini, Rome) on the functional and structural characterisation of the NS3 serine protease from the Hepatitis C Virus. This activity has led to the filing and extension of two patents application by MSD. Upon gaining the PhD title he moved to Heidelberg (Germany) at the European Molecular Biology Laboratory (EMBL) in the Structural Biology Programme (1998-2001) where he has pursued structural and functional investigation on integral membrane protein complexes. Following this experience he moved as a visiting scientist at the German Cancer Research Centre (Deutsches Krebsforschungszentrum) in the Analitycal Protein Chemistry unit where he has dedicated most of the investigations in the proteomics area. In his scientific experience he has been involved in protein characterisation by a number of different techniques. Mass spectrometry characterisation and identification of proteins represent the light motif of the laboratory he has developed during the last ten years. He has been the President of the Italian Proteomics Association (ItPA) years 2010-2015 and President of the European Proteomics Association (EuPA) for the years 2015-present. His international publication record is represented by over 200 contributions on journal with peer review system for a total impact factor above 600, his h-index is 40 based on approx. 5103 citations (SCOPUS, Elsevier, February 2019).
Stan Z. Li 李子青
Westlake Universisty, 西湖大学
He received his Ph.D. degree from Surrey University, UK, in 1991. He was awarded Honorary Doctorate of Oulu University, Finland, in 2013. He was the director of the Center for Biometrics and Security Research (CBSR) , Chinese Academy of Sciences, 2004~2019. He worked at Microsoft Research Asia as a Research Lead, 2000~2004. Prior to that, he was an associate professor (tenure) at Nanyang Technological University, Singapore. He joined Westlake University as a Chair Professor of Artificial Intelligence in February, 2019. His current interests include fundamental research in machine learning, data science, and applied research in multiple AI-related interdisciplinary fields (computer vision, smart sensors, life science, material science, and environmental science).
汪道文
Tongji Medical College, Huazhong University for Science & Technology
Dean of Department of Cardiology, TJH; Member of Chinese Society of Cardiology; Vice-President of Chinese Association of Cardiology in Hubei; Expert of National Cardiovascular Center, Ministry of Health; Standing Committee of Chinese Association of Pharmaceutical Biotechnology biological samples library Branch Member of American Heart Association, Member of International Society of Hypertension; Executive director of the Chinese Hypertension League Council; Expert in Expert Database of Hubei occupational health assessment; Member of second group of Hubei Medical Association Medical Malpractice Expert; Editorial Board of ISRN Cardiology; Editorial Board of Chinese Journal of Cardiovascular diseases; Associate Editor of Chinese Journal of Molecular Cardiology; Associate Editor of Journal of Internal Intensive Medicine; Editorial Board of Chinese Journal of Circulation; Editorial Board of Chinese Journal of Hypertension; Editorial Board of Journal of Clinical Cardiology and Journal of Clinical Internal Medicine; Editorial Board of Chinese Journal of Chinese Journal of Geriatric Heart Brain and Vessel Diseases; Reviewers of Regenerative Medicine, Gene Therapy, Stroke, Human Gene Therapy, Hypertension, JACC, Apoptosis, and other over ten kinds of journals.
Min Huang 黄敏
Thermo Fisher Scientific
Min Huang, PhD, current senior application engineer of life science mass spectrometry in Thermo Fisher Scientific, responsible for the technique development and application support of mass spectrometry related to proteomics and structural biology
Tiannan Guo 郭天南
Westlake Universisty, 西湖大学
Tiannan GUO, Ph.D. School of Life Sciences. Tiannan received training of clinical medicine (1999-2006) in Tongji Medical College, Huazhong University of Science and Technology, and learned biology (2001-2005) in Wuhan University, China, before he moved to Singapore for PhD training in cancer proteomics (2008-2012) in the laboratories of Dr. Newman Sze in Nanyang Technological University and Dr. Oi Lian Kon in National Cancer Centre Singapore. In 2012, Tiannan started his postdoctoral training in the laboratory of Dr. Ruedi Aebersold in ETH Zurich. Tiannan moved to Sydney as the Scientific Director of ProCan, group leader of Cancer Proteome, conjoint senior lecturer in Sydney Medical School, The University of Sydney, in March 2017. Tiannan joined the Westlake Institute for Advanced Studies in August 2017 as a Tenure Track Assistant Professor.
Opening
08:50-09:00 Beijing
19:50-20:00(-1) Boston
0:50-01:00 London
11:50-12:00 Sydney
01:50-02:00 Zürich
Introduction and Overview
Stephen Pennington (University College Dublin)
Fuchu He 贺福初 (National Center for Protein Sciences, Beijing)
Tiannan Guo 郭天南 (Westlake University)
Welcome from the president of Westlake University
09:00-09:10 Beijing
20:00-20:10(-1) Boston
01:00-01:10 London
12:00-12:10 Sydney
02:00-02:10 Zürich
Yigong Shi 施一公 (Westlake University)
Section A1: Proteomics for biomedical research and clinical medicine
Coordinators:
Ping Xu 徐平 ( National Center for Protein Sciences, Beijing)
Stan Z. Li 李子青 ( Westlake University)
Tiannan Guo 郭天南 (Westlake University)
09:10-09:26 Beijing
20:10-20:26(-1) Boston
01:10-01:26 London
12:10-12:26 Sydney
02:10-02:26 Zürich
蛋白质组学与肿瘤标志物的研究（结直肠癌）
Shu Zheng 郑树 (Zhejiang University)
郑树教授主要介绍了通过基因组学与蛋白质组学检测手段，对大肠癌患者的组织、血浆、血液中外泌体样本进行检测，揭示了结直肠癌发生发展过程中蛋白组和基因表达的变化，发现并验证了多个肿瘤标志物，为结直肠癌的早期诊断和精准治疗提供理论基础。
09:26-09:45 Beijing
20:26-20:45(-1) Boston
01:26-01:45 London
12:26-12:45 Sydney
02:26-02:45 Zürich
蛋白组学在感染性疾病的临床及基础研究中的应用
Lanjuan Li 李兰娟 (Zhejiang University)
09:45-10:08 Beijing
20:45-21:08(-1) Boston
01:45-02:08 London
12:45-13:08 Sydney
02:45-03:08 Zürich
PDPM: proteomics-driven precision medicine
Fuchu He 贺福初
Talking language: Chinese
Slide language: English
(National Center for Protein Sciences, Beijing)
10:08-10:23 Beijing
21:08-21:23(-1) Boston
02:08-02:23 London
13:08-13:23 Sydney
03:08-03:23 Zürich
How should prognostic and predictive biomarkers be evaluated?
Ruiping Xiao 肖瑞平
Talking language: English
Slide language: English
(Peking University & Associate Editor, NEJM)
Dr. Ruiping Xiao briefly introduce the history, the focuses and review processes of NEJM. Recently the they prefers creative medical breakthrough, and take 21-gene as a prognostic biomarker in breast cancer as an example. Finally, he summarized the talents and limits of the application of proteomics study in clinical researches, and also gave some corresponding solutions.
10:23-10:30 Beijing
21:23-21:30(-1) Boston
02:23-02:30 London
13:23-13:30 Sydney
03:23-03:30 Zürich
Questions, Recommendations and Conclusions
Section A2: Proteomics for biomedical research and clinical medicine
Coordinators:
Jimin Shao 邵吉民 (Zhejiang University)
Tiannan Guo 郭天南 (Westlake University)
10:30-10:46 Beijing
21:30-21:46(-1) Boston
02:30-02:46 London
13:30-13:46 Sydney
03:30-03:46 Zürich
Drug discovery and proteomics
Hong Shen 沈宏
Talking language: English
Slide language: English
(Roche Innovation Center Shanghai)
Mass spectrometry-based proteomics is a powerful technology to profile proteome and monitor protein communities in drug discovery. The applications in drug discovery demonstrate the impact of mass spectrometry-based proteomics in target and off-target identification, the understanding of PPI & biological pathways, time-, space- and dose-dependent signaling events mediated by PTMs, etc. Future directions could be to evaluate protein communities more often in vivo, to measure stoichiometry of proteins, and to provide methods for clinical samples.
10:46-11:05 Beijing
21:46-22:05(-1) Boston
02:46-03:05 London
13:46-14:05 Sydney
03:46-04:05 Zürich
蛋白质组学临床应用
Xiujun Cai 蔡秀军
Talking language: Chinese
Slide language: Chinese
(Sir Run Run Shaw Hospital, Zhejiang University)
11:05-11:25 Beijing
22:05-22:25(-1) Boston
03:05-03:25 London
14:05-14:25 Sydney
04:05-04:25 Zürich
Potential roles of proteomics in a City Brain
Xiansheng Hua 华先胜
Talking language: Chinese
Slide language: English
(City Brain & VP, Artificial Intelligence Center, Alibaba)
城市大脑对城市进行4维时空建模，需要Video, GPS，Coil，Bus等数据。城市大脑可以为医疗健康领域赋能。城市大脑和人体的循环系统（人体的运作）等有异曲同工之妙。可以利用大数据的技术对药物靶点进行优化（疫苗，抗原设计）。
11:25-11:45 Beijing
22:25-22:45(-1) Boston
03:25-03:45 London
14:25-14:45 Sydney
04:25-04:45 Zürich
COVID-19 and cardiac injury
Daowen Wang 汪道文
Talking language: English
Slide language: English
(Tongji Medical College, Huazhong University for Science & Technology)
In severe COVID-19 patients, the levels of heart biomarkers upregulate. Cardiac injure might cause by cytokine storm. RAAS inhibitors will increase ACE2 expression leading to the occur of Cardiac Injure?
11:45-11:57 Beijing
22:45-22:57(-1) Boston
03:45-03:57 London
14:45-14:57 Sydney
04:45-04:57 Zürich
Standardization and harmonization of multi-center proteotype analysis supporting translational studies
Min Huang 黄敏
Talking language: English
Slide language: English
(Thermo Fisher Scientific)
High resolution MS1-DIA workflow-digital biobank: the standardization method includes defined QC, optimized LC separation and efficient data acquisition. Tow kinds samples: QC samples (Commercial HeLa peptides) and controlled samples (mixture of HeLa, yeast and E.coli). several QC criteria for LC and MS performance: media LC peak, number of MS1, MS2 data points, precursor ID, proteins ID and inter-injection median CV of precursors.QC-standard: Three injections per day were needed. Inter-day and inter-lab reproducibility: over 80% of the total quantification proteins were quantified on each day or locally. Quantification accuracy and precision: the median values were lower than 10% deviation for human and yeast proteins and lower than 20% deviation for E.coli proteins. Median CV were lower 5% for the human and yeast proteins and 10% for E.coli. Application: Archival ovarian cancer tissue-clear cell and high grade serous, 5721 unique protein groups were identified from all tumor samples, 394 significantly dysregulation proteins between the two types of ovarian cancer samples. Use a streamlined HRMS1-DIA workflow to acquire data and analyze.Clinical Study: 5712 proteins were identified from all tumor samples, 394 significantly altered proteins between those two types of ovarian cancer samples.
11:57-12:20 Beijing
22:57-23:20(-1) Boston
03:57-04:20 London
14:57-15:20 Sydney
04:57-05:20 Zürich
Questions, Recommendations and Conclusions
Lunch Break
Section B: Proteomics and beyond
Coordinators:
Edouard Nice (Monash University)
Catherine Wong 黄超兰 (Peking University)
Tiannan Guo 郭天南 (Westlake University)
13:00-13:20 Beijing
00:00-00:20 Boston
05:00-05:20 London
16:00-16:20 Sydney
06:00-06:20 Zürich
Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression
Yu-Ju Chen
Talking language: English
Slide language: English
(Academia Sinica)
Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression Proteogenomics reveals signaling network of driver gene, such as EGFR, KRAS, which have been as effective drug targets.
In the genome level, East Asia is mainly induced by EGFR, while USA is mainly induced by KRAS mutation. The unmet clinical needs in late stage patients focus on seeking effective drug targets.
High quality specimens and analytical pipeline as the support.
In the early stage, higher APOBEC mutation signature in female with short survival but better response to immunotherapy.
The downstream of MAPK signaling cascade in EGFR-Mt/WT patient Protein network of proteomics for drug target
13:20-13:40 Beijing
00:20-00:40 Boston
05:20-05:40 London
16:20-16:40 Sydney
06:20-06:40 Zürich
基于代谢组学方法发现结直肠癌诊断标志物
Maode Lai 来茂德
Talking language: Chinese
Slide language: Chinese
(China Pharmaceutical University)
来茂德教授通过利用代谢组学手段，对健康/代谢综合征/结直肠癌人群的血清样本进行非靶向代谢组学检测，找到30个候选代谢物，进一步在1594个样本中进行进一步验证，最终得到7个潜在代谢物，并对其与临床参数相关性进行描绘。最终从7个代谢物简化到2个代谢物，并在独立队列中得以验证。本研究对结直肠癌诊断提供新方法新思路
13:40-14:00 Beijing
00:40-01:00 Boston
05:40-06:00 London
16:40-17:00 Sydney
06:40-07:00 Zürich
Metabolomics and precision medicine
Huiru Tang 唐惠儒
(Fudan University)
14:00-14:20 Beijing
01:00-01:20 Boston
06:00-06:20 London
17:00-17:20 Sydney
07:00-07:20 Zürich
AI for life sciences
Stan Z. Li 李子青
Talking language: English
Slide language: English
(Westlake University)
Prof. Li introduces how to study omic researches by AI based strategy. Firstly, introduce AI and proteomic strategies assist cancer diagnosis, then give an example: differential diagnosis of benign and malignant thyroid nodules. The type of thyroid nodules is able to diagnose by artificial neural network, meanwhile provide another method for classifying cancer type by proteomic profiling. Secondly, introduce a novel high-dimensional data analysis method, which is called Deep Manifold Transformation (DMT). Compared with t-SNE and UMAP, the results demonstrated DMT is much better in many aspects, such as dimensionality reduction, clustering, visualization and so on. As far as possible, the global structure and serial characteristics of data are guaranteed in the low dimensional space and have good application results in single cell data.
14:20-14:30 Beijing
01:20-01:30 Boston
06:20-06:30 London
17:20-17:30 Sydney
07:20-07:30 Zürich
Questions, Recommendations and Conclusions
14:30-15:00 Beijing
01:30-02:00 Boston
06:30-07:00 London
17:30-18:00 Sydney
07:30-08:00 Zürich
Tea break
Section C1: Emerging proteomics technologies
Coordinators:
Stephen Pennington (University College Dublin)
Yu-Ju Chen (Academia Sinica)
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
15:00-15:45 Beijing
02:00-02:45 Boston
07:00-07:45 London
18:00-18:45 Sydney
08:00-08:45 Zürich
Technology and applications of MS-based proteomics to body fluid and tissue analysis
Matthias Mann (Max Planck Institute)
These years they focus more on clinical applications than cellular biology, and that’s what the following 5 parts (technology, PTM, plasma proteome profiling，single cell proteomics and deep visual proteomics) will be related with.
Technology (Introduction of two software and one hardware)
AlphaPept Framework: --a super-fast framework for the analysis of MS-based proteomics--open source, codebase by python and UI solution for non-experts--Python combined with Numba package make the analysis ultrafast the Clinical Knowledge Graph (CKG)--integrates proteomics data into clinical decision-making--Open source tool for data integration, analysis (the latest statistical and machine learning algorithms included) and interpretation (based on relevant experimental data, public databases and the literature)
Trapped ion mobility spectrometry (TIMS)--Ion mobility separation Parallel Accumulation – Serial Fragmentation (PASEF)
--Increased signal-to-noise by signal compression
--Full precursor mass resolution
--Multiplied sensitivity and sequencing speed
--diaPASEF could be more robust for future clinical proteomics
Post-translational modifications
(LRRK2 in Parkinson’s disease)
Method: Phosphoproteomics simplified protocol EasyPhos
Application: hunt for substrates of multidomain Leucine-rich repeat kinase 2 (LRRK2)
--genetic cause of Parkinson’s disease: pathogenic mutations of LRRK2.
--G2019S substitution on LRRK2 protein activates the kinase
--genetics (cells from genetically modified mice), pharmacology (selective LRRK2 inhibitors), phosphoproteomics (EasyPhos, 27,000 phosphosites on ~6000 proteins)
--Rab10 and Rab12 are phosphorylated by LRRK2
Plasma proteome profiling (liver disease)
Application: diagnostic tool for early detection of liver disease
Study 1: plasma proteomics identified novel proteins associated with non-alcoholic fatty liver disease (NAFLD)
--plasma proteome of 3 matched sub-cohorts by BoxCar acquisition
--in cirrhotic liver, 77% downregulated plasma proteins are “liver-specific”
--six proteins significantly associated with NAFLD
--global correlation of plasma proteins and clinical parameters (liver enzymes)
--In HFD-induced NAFLD mouse model, identified maker candidates in human cohort recapitulated similar changes, providing evidence that these proteins may be good biomarkers.
Study 2: proteomics identified circulating protein markers for alcohol-related liver disease (ALD)
--a paired plasma (N=596) and liver tissue (N=79) proteome profiling
--of the 407 overlapped proteins between liver and plasma, 91 had significant correlations
--52 co-regulated proteins in the plasma and liver display distinct temporal patterns across fibrosis stages.
--machine learning models based on plasma proteome to predict early-stage of fibrosis, inflammation and steatosis, which outperform existing tests
Single cell proteomics
In EvoTip single cell processing and Evosep liquid chromatography for ultra high-sensitivity single cell proteomics.
~1000 protein groups identified with high quantitative reproducibility at the single cell level (Hela cell line).
Deep visual proteomics
Workflow: High-parametric images with subcellular resolution of archived patient tissue samples – image segmentation with deep learning training – machine learning algorithms to predict cellular phenotypes – single-cell isolation (including with subcellular spatial resolution or other arbitrary structures) using laser capture microdissection – cell type specific proteomes – Clinical Knowledge Graph – resource for researchers and clinicians
15:45-16:30 Beijing
02:45-03:30 Boston
07:45-08:30 London
18:45-19:30 Sydney
08:45-09:30 Zürich
The modular proteome and its clinical significance
Ruedi Aebersold (ETH Zurich)
Ruedi tried to find out how alterations in the molecular constellation determines alterations in function/phenotype from three aspects.
1. How does genomic variability affect proteotype composition and phenotype? Method:Multi-layer molecular profiles for Hela cells with different phenotypes (e.g. doubling time and the ability to be infected)Effect of genomic variability on molecular profiles and phenotypes was calculated. Conclusion: Genotypic variability propagates along the axis of the central dogma in poorly predictable ways.Organization of proteins into complexes acts as a significant buffer of genotype variability.
2. How does genomic variability affect proteotype organization and deterministic functions? Method: Size exclusion chromatography mass spectrometry (SEC-MS) and size exclusion chromatography algorithmic toolkit (SECAT) Compute effect of genotypic variation on protein complexes and protein interaction networks. Results: Genomic variability affects the proteotype organization at the level of complexes and PPIs. Conclusion: New MS method and algorithms enable us to relate function to phenotype.
3.How can we predict altered proteotype modules and deterministic functions from transcript or protein profiles? Method: Proteome abundance profiles by SWATH/DIA Evaluation of changes in modularity based on changes in co-expression covariance and observing different deterministic functions, they tried to find out the relationship between these features. Conclusion: Proteins in the same complex (e.g. ATP synthase subunit alpha) tend to correlate across different samples. Different stage of prostate cancers exhibit altered quantitative relationships in many protein pairs. Genomic variants can alter specific protein modules and thus their function.
16:30-16:45 Beijing
03:30-03:45 Boston
08:30-08:45 London
19:30-19:45 Sydney
09:30-09:45 Zürich
Mattias Q&A
16:45-17:00 Beijing
03:45-04:00 Boston
08:45-09:00 London
19:45-20:00 Sydney
09:45-10:00 Zürich
Ruedi Q&A
Section C2: Emerging proteomics technologies
Coordinators:
Yu-Ju Chen (Academia Sinica)
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
17:25-17:50 Beijing
04:25-04:50 Boston
09:25-09:50 London
20:25-20:50 Sydney
10:25-10:50 Zürich
Technologies for high-throughput clinical proteomics
Bernhard Küster (Technische Universität Muenchen)
Benhard develops MS-based technologies for high-throughput at high quality.
1, analysis of body fluids and whole proteomes by micro-LD MS/MS.The 50 uL/min LC flow generates stable performances while high quality. Data from 1500 consecutive injections showed high retention time consistence. It was also applied to analyzed the phosphoproteomes of 377 cancer cell line and quantified 12,700 proteins in total and 12000 p-sites.
2, analysis of FFPE material by single-shot LC-FAIMS-MS/MS.The optimized workflow also generates high ids (~30,000 peptides) per shot with low CVs.
3, Prosit prediction of spectral libraries and re-scoring of LC-MS/MS data.The great effort made on Prosit establishment can predict fragment patterns and retention time with high precision, and is currently serving the scientific community very well.
17:50-18:15 Beijing
04:50-05:15 Boston
09:50-10:15 London
20:50-21:15 Sydney
10:50-11:15 Zürich
Clinical proteomics in interesting times
Roman Fischer (University of Oxford)
18:40-19:02 Beijing
05:40-06:02 Boston
10:40-11:02 London
21:40-22:02 Sydney
11:40-12:02 Zürich
Single cell proteomics (SCP): glass-Oil-Air-Droplet (gOAD) pico chip
Catherine Wong (Peking University)
19:02-19:10 Beijing
06:02-06:10 Boston
11:02-11:10 London
22:02-22:10 Sydney
12:02-12:10 Zürich
Dinner break
Section D: Industrialized proteomics for the clinic
Coordinators:
Stephen Pennington (University College Dublin)
Yu-Ju Chen (Academia Sinica)
Andrea Urbani (Università Cattolica del "Sacro Cuore")
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
20:00-20:17 Beijing
07:00-07:17 Boston
12:00-12:17 London
23:00-23:17 Sydney
13:00-13:17 Zürich
Development of a pipeline for biomarker discovery using proteomics
Anthony Whetton (The University of Manchester)
Introduce the concept of precision medicine and genomic/proteomic applications in precision medicine nowadays. Further explain why we need to discover biomarkers; the reason is that individuals have differential responses for the same drugs or therapies. Briefly introduce Stoller Biomarker Discovery Center in Manchester and industrializing clinical proteomic strategies. Anthony focuses on SWATH-MS based plasma proteomics and gives some examples used industrializing clinical proteomic strategies: 1) grey platelet syndrome 2) chronic kidney disease. UK Biobank has had genomic data and its proteomic analysis of plasma/urine/mixed saliva is planned now.
20:17-20:40 Beijing
07:17-08:40 Boston
12:17-12:40 London
23:17-00:40(+1) Sydney
13:17-13:40 Zürich
Procan-adapting proteomics for the cancer clinic
Roger Reddel (The University of Sydney)
20:40-21:00 Beijing
07:40-09:00 Boston
12:40-13:00 London
23:40-01:00(+1) Sydney
13:40-14:00 Zürich
Break
Section E: Translational proteomics
Coordinators:
Stephen Pennington (University College Dublin)
Yu-Ju Chen (Academia Sinica)
Jun Qin (National Center for Protein Sciences, Beijing)
Edouard Nice (Monash University)
Tiannan Guo (Westlake University)
21:00-21:30 Beijing
08:00-08:30 Boston
13:00-13:30 London
00:00-00:30(+1) Sydney
14:00-14:30 Zürich
Translation of protein biomarkers: It’s simple
Stephen Pennington (University College Dublin)
New protein biomarkers will be complimentary to genomics to promote precision medicine. The protein biomarker pipeline includes discovery, confirmation assay development, evaluation/validation and approval/adoption. The sample amounts and detection methods for each stage are different. The authors suggested the application of MRM in the confirmation and evaluation stages.
Dr. Pennington presented one of his study about developing blood biomarkers for discriminate patients with psoriatic arthritis (PsA) and Rheumatoid Arthritis (RA). Before that, there were no criteria to distinguish PsA form RA or other arthropathies. After comparing the serum proteomic profiles between PsA and RA patients using MS-based labeled proteomics, SOMAscan and Luminex, they found some unbiased biomarker candidates. They further supplement the biomarker candidates with existing panel and literature to make a panel called PAPRICA containing ~200 proteins and >400 peptides for the following MRM analysis. They have tested the panel on a new cohort containing 169 patients and achieved an AUC of 0.9 using normalized MS data. They ‘ll further evaluate the panel in a larger cohort containing 1000 patients
21:30-21:48 Beijing
08:30-08:48 Boston
13:30-13:48 London
00:30-00:48(+1) Sydney
14:30-14:48 Zürich
Psychiatric disorder pathway illumination using omics
Chris W. Turck (Max Planck Institute of Psychiatry)
Psychiatric disorders have a great effect on the physical health of modern people. The diagnosis of psychiatric disorders is difficult using barely the clinical determined factors or indicators. People have been applying omics technologies to study psychiatric disorders, and comparing with the results of genomic characterization, the results of proteome/metabolome/microbiome characterization vary from day to day, herein could better reflect the psychiatric conditions, feasible for this type of study. In Psychiatric disorder biomarker study, animal models and body fluid from patients can be the substitutes for the human brain tissue because of their easy access.
To study the biosignatures of anxiety disorder, Dr. Turck and his team created the stress susceptible DBA/2NCrl and C57BL/6NCrl mice and performed transcriptomic proteomic analysis of the brain tissue of susceptible mice. They found:
1) opposite regulation of the same mitochondria related genes in DBA/2NCrl and C57BL/6NCrl stress susceptible mice, which indicated the gene background affects the stress-induced behaviors
2) blood gene expression of mitochondria related genes in panic disorder patients resembles DBA/2NCrl stress susceptible mice but in lower intensity
Dr. Turck demonstrated the alterations of mitochondria related genes in anxiety and panic disorder, and further stated that these studies are still far from clinical insights.
22:15-22:40 Beijing
09:15-09:40 Boston
14:15-14:40 London
01:15-01:40(+1) Sydney
15:15-15:40 Zürich
Questions, Recommendations and Conclusions
Concluding remarks
22:40-23:00 Beijing
09:40-10:00 Boston
14:40-15:00 London
01:40-02:00(+1) Sydney
15:40-16:00, Zürich
Tiannan Guo 郭天南 (Westlake University)
Matthias Mann (Max Planck Institute)
Jun Qin 秦钧 (National Center for Protein Sciences, Beijing)
Edouard Nice (Monash University)
Stephen Pennington (University College Dublin)
Acknowledgements